Mammography Devices Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product Type (Full-field Digital Mammography, Film-screen Mammogram, Breast Tomosynthesis), By Technology (Digital, Analog), By End User (Hospitals & Clinics, Diagnostic Centres, Others), By Region & Competition, 2021-2031F

Market Overview

The Global Mammography Devices Market is projected to grow from USD 3.13 Billion in 2025 to USD 4.47 Billion by 2031 at a 6.12% CAGR. Mammography devices are essential medical imaging tools that utilize low-dose X-rays to capture detailed images of breast tissue for the early detection and diagnosis of breast cancer, encompassing technologies such as digital mammography and breast tomosynthesis. The market for these devices is primarily driven by the increasing global incidence of breast cancer, coupled with rising awareness about early detection and the importance of routine screening programs. Furthermore, the aging global female population and supportive government initiatives promoting breast health contribute significantly to sustained market expansion.

A considerable challenge impeding market growth is the global shortage of adequately trained radiologists and other medical professionals essential for operating and interpreting mammography results effectively. Despite this, the increasing prevalence of breast cancer underscores the need for these devices. According to the American Cancer Society, in 2026, approximately 321,910 women are projected to be diagnosed with invasive breast cancer in the United States, highlighting the critical demand for early diagnostic solutions.

Key Market Drivers

The rising global incidence of breast cancer stands as a primary catalyst for the expansion of the mammography devices market. This increasing prevalence necessitates widespread adoption of early detection methods to improve patient outcomes and survival rates. According to an analysis published in The Lancet Oncology in March 2026 by the Global Burden of Disease Study Breast Cancer Collaborators, an estimated 2.3 million new breast cancers were diagnosed worldwide in women in 2023, underscoring the substantial and ongoing demand for effective diagnostic tools. This pervasive health challenge drives healthcare providers globally to enhance their screening capabilities, thereby fueling the procurement of advanced mammography systems.

Technological advancements in imaging devices represent another significant growth driver, continuously reshaping the capabilities and efficacy of mammography. Innovations such as 3D tomosynthesis and artificial intelligence powered diagnostics offer improved image clarity, reduced recall rates, and enhanced detection of subtle lesions, encouraging upgrades and new installations. Highlighting this commitment to innovation, Siemens Healthineers invests approximately €2 billion in research and development during 2024–2025 to sustain continuous product advancements across its imaging portfolio. These technological leaps are crucial for attracting investment and fostering market penetration. Furthermore, demonstrating broader governmental and industry commitment to improving breast cancer care, Alberta's government, in partnership with Siemens Healthineers and the Alberta Cancer Foundation, announced in March 2025 an investment of $800 million CAD over eight years to improve cancer care and support early detection.

Download Free Sample Report

Key Market Challenges

A considerable challenge impeding market growth for global mammography devices is the scarcity of adequately trained radiologists and other medical professionals crucial for effective operation and interpretation of mammography results. This shortage directly curtails the capacity of healthcare facilities to conduct breast cancer screenings and diagnostic procedures, despite the increasing demand for early detection. When there are insufficient qualified personnel, the full utilization of advanced mammography equipment, including newer digital and tomosynthesis systems, becomes compromised.

Facilities may delay or reduce screening appointments, leading to underutilization of existing devices and a reluctance to invest in new technologies, thereby hampering market expansion. According to a 2026 survey by the Society of Breast Imaging, 79% of practices reported being short-staffed in breast imaging. This pervasive staffing issue restricts the throughput of mammography centers and creates significant bottlenecks in patient access to vital screening services, directly impeding the growth trajectory of the mammography devices market.

Key Market Trends

The growing integration of artificial intelligence into diagnostic workflows represents a significant trend reshaping the global mammography devices market by enhancing operational efficiency and diagnostic confidence. AI algorithms are increasingly deployed to automate repetitive tasks, triage high-risk cases, and provide decision support, thereby optimizing the entire screening process. This integration helps address radiologist shortages and increasing screening volumes. For example, according to the results of the GEMINI study published in Nature Cancer, March 2026, the integration of AI into screening workflows led to reductions in workload by up to 31% in the United Kingdom. This efficiency gain enables healthcare providers to manage more cases with existing resources, accelerating patient throughput and improving access to timely diagnoses.

Another pivotal trend is the continuous advancement in specialized imaging modalities, particularly Contrast-Enhanced Mammography and Molecular Breast Imaging. These technologies offer crucial supplemental screening options, especially for women with dense breast tissue where conventional mammography may have limitations. Contrast-Enhanced Mammography provides functional information by highlighting vascularity in suspicious lesions. Similarly, Molecular Breast Imaging uses a radioactive tracer to detect metabolically active cancerous cells. According to a 2025 analysis of the Density MATTERS Trial, presented at ARRS 2026, Molecular Breast Imaging detected an additional 6.7 cancers per 1,000 screenings one year after digital breast tomosynthesis screening. These advancements expand the diagnostic toolkit, leading to more personalized and effective breast cancer screening strategies.

Segmental Insights

The Digital Mammography segment is experiencing rapid growth within the Global Mammography Devices Market, primarily driven by continuous technological advancements that enhance diagnostic accuracy and operational efficiency. This includes improvements in image resolution, faster processing times, and superior contrast visualization, particularly beneficial for women with dense breast tissue. The increasing global prevalence of breast cancer and heightened awareness about the importance of early detection further stimulate demand for these advanced systems. Moreover, the integration of artificial intelligence for enhanced image interpretation and streamlining workflow, alongside supportive regulatory frameworks such as updates to the Mammography Quality Standards Act (MQSA) and past reclassifications by the U.S. Food and Drug Administration (FDA), contribute significantly to accelerated market adoption.

Regional Insights

North America leads the Global Mammography Devices Market, primarily driven by its highly developed healthcare infrastructure and widespread awareness regarding breast cancer screening and early detection. The region benefits from robust government initiatives, including established screening programs and public health campaigns, which encourage regular check-ups. Favorable reimbursement policies and substantial healthcare expenditure further support the widespread adoption of advanced mammography technologies, such as digital mammography and 3D tomosynthesis. This combination of factors, alongside continuous technological advancements, ensures North America maintains its leading position in the market.

Recent Developments

• In November 2025, GE HealthCare received U.S. FDA Premarket Authorization for Pristina Recon DL, an advanced 3D mammography image reconstruction technology. This innovation, powered by deep learning, enhances the image definition and sharpness of digital breast tomosynthesis (DBT) scans. As an enhancement to GE HealthCare's Pristina Via system, it aims to deliver exceptional image quality without increasing patient radiation dose. This development represents a significant advancement in diagnostic clarity for the global mammography devices market, supporting clinicians in making more confident diagnoses.
• In November 2025, Siemens Healthineers introduced significant enhancements to its MAMMOMAT B.brilliant mammography systems at RSNA. These updates expanded the system's contrast-enhanced mammography and biopsy capabilities. A newly developed ClearCEM image-reconstruction technique was integrated to provide clearer enhancement and consistent image quality, particularly supporting diagnostics in dense breast tissue. This advancement enables improved lesion detection and facilitates faster diagnoses, further solidifying the system's role within the global mammography devices market.
• In May 2025, Hologic's Genius AI Detection PRO solution was recognized as the "Best New Imaging Technology Solution" by MedTech Breakthrough. This advanced AI-powered mammography technology is designed to enhance breast cancer detection by analyzing current and prior patient exams, improving specificity, and identifying suspicious areas more effectively. The solution aims to streamline radiologists' workflows, potentially reducing overall reading time. This acknowledgment highlights Hologic's continuous efforts in integrating artificial intelligence into mammography devices for improved screening accuracy.
• In March 2025, iCAD announced a new strategic reseller partnership with Koios Medical at ECR 2025. This collaboration aims to deliver a comprehensive, multi-modality artificial intelligence suite for breast cancer detection. The partnership integrates iCAD's ProFound AI® Breast Health Suite, which focuses on mammography, with Koios SmartUltrasound™. This collaboration is designed to provide radiologists with an enhanced AI-powered pathway spanning from initial breast cancer screening through diagnosis, offering a more complete diagnostic solution.

Key Market Players

• Hologic Inc.
• Fujifilm Holdings Corporation
• Philips Healthcare
• Siemens Healthineers AG
• GE Healthcare
• Carestream Health Inc.
• Konica Minolta Inc.
• Delphinus Medical Technologies Inc.
• Analogic Corporation
• KUB Technologies Inc.

Report Scope:

In this report, the Global Mammography Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Mammography Devices Market , By Product Type:

• Full-field Digital Mammography
• Film-screen Mammogram
• Breast Tomosynthesis

• Mammography Devices Market , By Technology:

• Digital
• Analog

• Mammography Devices Market , By End User:

• Hospitals & Clinics
• Diagnostic Centres
• Others

• Mammography Devices Market , By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE